Obsidian Therapeutics CEO and leadership

Experienced Board Member, Inventor and Serial Entrepreneur with a demonstrated history of success in the biotechnology industry. Skilled in Biotechnology, Product Development, Life Sciences and Transactions. Strong business development professional with a Ph.D. focused in Pharmaceutical Sciences from the University of Nottingham. Winner EY Entrepreneur of the Year 2014, NJ Region.

Strategic finance professional with significant capital raising and mergers and acquisitions experience. Experience includes financing, asset searches, transaction advisory, corporate positioning, and transaction preparation (including interfacing with Wall Street institutions and deal structuring).

Transaction experience includes over 40 equity and debt transactions raising more than $7 billion (including an IPO as a CFO) and 15 announced M&A transactions.

Specialties: Private financings, Initial Public Offerings (IPOs), Follow-ons, Partnering, Mergers and Acquisitions

Gary Vanasse is a CMO and SVP at Obsidian Therapeutics.

Jan Henrik Ter Meulen is a Board Member at Virometix AG, Board of Directors at Virometix AG, and Chief Scientific Officer at Obsidian Therapeutics and is based in Boston, Massachusetts. He has worked as Postdoctoral Fellow at DKFZ German Cancer Research Center; International Research Scholar in Infectious Diseases and Parasitology at HOWARD HUGHES MEDICAL INSTITUTE; and Exec Dir:Vaccine Research at MERCK & CO., INC.. Jan studied at Philipps-Universität Marburg between 2000 and 2003, Freiburg between 1980 and 1986, and Univ of London Medical Schl.

Jennifer Peterson is a Chief People Officer at Obsidian Therapeutics and is based in Cambridge, Massachusetts. She has worked as VP of People at Inari. Jennifer attended Franklin & Marshall College between 1984 and 1989, Cornell University, and CTI - Communication Trend Italia.

Catherine Stehman-Breen is a Chief Development Officer at Obsidian Therapeutics, Board Member at Generation Bio Co, and Chief Executive Officer at Chroma Medicine and is based in Cambridge, Massachusetts. She has worked as Entrepreneur-In-Residence at Atlas Venture; VP:Clinical Dev & Regulatory Affairs at REGENERON PHARMACEUTICALS, INC.; and Executive Director Global Development at Amgen. Catherine attended The University of Chicago Pritzker School of Medicine between 1986 and 1990, University of Washington between 1994 and 1996, and Lyons Township High School between 1977 and 1981.

Experienced Board Member, Inventor and Serial Entrepreneur with a demonstrated history of success in the biotechnology industry. Skilled in Biotechnology, Product Development, Life Sciences and Transactions. Strong business development professional with a Ph.D. focused in Pharmaceutical Sciences from the University of Nottingham. Winner EY Entrepreneur of the Year 2014, NJ Region.